---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-376723"
form_type: "8-K"
ticker: "PMVP"
cik: "0001699382"
company_name: "PMV Pharmaceuticals, Inc."
filed_at: "2026-08-31T20:06:01+00:00"
generated_at: "2026-08-31T20:07:10.584189+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# PMV Pharma reports 46% ORR in ovarian cancer cohort; NDA submission planned Q1 2027

## Summary
- ORR of 46% (35/76) in ovarian cancer cohort; median duration of response 10.0 months, median time to response 1.3 months.
- FDA feedback supports NDA for accelerated approval; submission planned Q1 2027.
- Enrollment for primary analysis in platinum-resistant/refractory ovarian cancer completed.
- Safety: mostly Grade 1/2 AEs, 5% discontinuation due to treatment-related AEs.
- Company to present update on all PYNNACLE cohorts at medical conference Q4 2026.

## SEC filing metadata
- accession: 0001193125-26-376723
- form_type: 8-K
- ticker: PMVP
- cik: 0001699382
- company_name: PMV Pharmaceuticals, Inc.
- filed_at: 2026-08-31T20:06:01+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1699382/000119312526376723/0001193125-26-376723-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1699382/000119312526376723/d441751d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-376723
- JSON: https://secwatch.observer/filing/0001193125-26-376723.json
- Plain text: https://secwatch.observer/filing/0001193125-26-376723.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.